Natera, Inc. (NASDAQ:NTRA) Shares Sold by LMR Partners LLP

LMR Partners LLP reduced its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 81.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,284 shares of the medical research company's stock after selling 14,524 shares during the quarter. LMR Partners LLP's holdings in Natera were worth $417,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of NTRA. Covestor Ltd increased its position in Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company's stock valued at $47,000 after purchasing an additional 95 shares during the period. GAMMA Investing LLC raised its position in shares of Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock worth $55,000 after purchasing an additional 106 shares during the last quarter. CIBC Asset Management Inc raised its holdings in Natera by 3.3% in the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company's stock worth $441,000 after buying an additional 111 shares during the last quarter. RiverPark Advisors LLC lifted its position in Natera by 3.5% in the 3rd quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company's stock valued at $425,000 after acquiring an additional 112 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC boosted its holdings in shares of Natera by 5.4% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company's stock valued at $336,000 after acquiring an additional 135 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Piper Sandler raised their target price on shares of Natera from $150.00 to $200.00 and gave the stock an "overweight" rating in a research note on Monday. Robert W. Baird raised their price target on Natera from $120.00 to $160.00 and gave the stock an "outperform" rating in a research note on Wednesday, November 13th. Morgan Stanley upped their price target on shares of Natera from $132.00 to $176.00 and gave the stock an "overweight" rating in a research report on Thursday, November 14th. Canaccord Genuity Group raised their price objective on Natera from $150.00 to $165.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Finally, StockNews.com cut Natera from a "hold" rating to a "sell" rating in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, Natera presently has an average rating of "Moderate Buy" and a consensus target price of $140.59.

Natera Price Performance

Shares of NASDAQ:NTRA traded up $5.78 on Wednesday, reaching $167.88. 2,033,270 shares of the company were exchanged, compared to its average volume of 1,347,088. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a 1-year low of $53.62 and a 1-year high of $169.71. The company has a 50-day moving average of $129.84 and a 200-day moving average of $117.00. The firm has a market cap of $22.16 billion, a price-to-earnings ratio of -95.39 and a beta of 1.53.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.31. The company had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company's revenue for the quarter was up 63.9% on a year-over-year basis. During the same period last year, the firm earned ($0.95) EPS. Equities analysts forecast that Natera, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Rowan E. Chapman sold 2,614 shares of Natera stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $127.68, for a total transaction of $333,755.52. Following the completion of the sale, the director now directly owns 7,969 shares in the company, valued at $1,017,481.92. The trade was a 24.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $128.48, for a total transaction of $645,483.52. Following the completion of the sale, the chief executive officer now directly owns 195,686 shares of the company's stock, valued at $25,141,737.28. The trade was a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,821 shares of company stock worth $4,776,878 over the last 90 days. 7.60% of the stock is currently owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.